These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10361873)

  • 21. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial.
    Carrier M; Robitaille D; Perrault LP; Pellerin M; Pagé P; Cartier R; Bouchard D
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):325-9. PubMed ID: 12579101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat.
    Miyake Y; Yokota K; Fujishima Y; Sukamoto T
    Blood Coagul Fibrinolysis; 2001 Jul; 12(5):349-57. PubMed ID: 11505077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease.
    Macchi L; Sarfati R; Guicheteau M; Chamlian V; Pourrat O; Gruel Y; Magnin G; Brizard A; Boinot C
    Clin Appl Thromb Hemost; 2000 Oct; 6(4):187-9. PubMed ID: 11030522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats.
    Fujishima Y; Yokota K; Sukamoto T
    Thromb Res; 1998 Sep; 91(5):221-7. PubMed ID: 9755834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT).
    Gerhardt A; Scharf RE; Zotz RB
    Clin Appl Thromb Hemost; 2009; 15(4):461-4. PubMed ID: 18840630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm.
    Ontachi Y; Asakura H; Arahata M; Kadohira Y; Maekawa M; Hayashi T; Yamazaki M; Morishita E; Saito M; Minami S; Nakao S
    Circ J; 2005 Sep; 69(9):1150-3. PubMed ID: 16127203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
    Ben Ami R; Rachmimov R; Berliner S
    Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
    Zöhrer' B; Zenz W; Rettenbacher A; Covi P; Kurnik K; Kroll H; Grubbauer HM; Muntean W
    Acta Paediatr; 2001 Jul; 90(7):765-71. PubMed ID: 11519979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulphate in skin basement membrane.
    van der Pijl JW; Daha MR; van den Born J; Verhagen NA; Lemkes HH; Bucala R; Berden JH; Zwinderman AH; Bruijn JA; van Es LA; van der Woude FJ
    Diabetologia; 1998 Jul; 41(7):791-8. PubMed ID: 9686920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
    Horlait G; Minet V; Mullier F; Michaux I
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
    Machida S; Onizuka M; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Ando K
    Bone Marrow Transplant; 2017 Feb; 52(2):307-309. PubMed ID: 27892947
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and efficacy of danaparoid (Orgaran) use in children.
    Bidlingmaier C; Magnani HN; Girisch M; Kurnik K
    Acta Haematol; 2006; 115(3-4):237-47. PubMed ID: 16549902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study.
    de Pont AC; Hofstra JJ; Pik DR; Meijers JC; Schultz MJ
    Crit Care; 2007; 11(5):R102. PubMed ID: 17854496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II.
    Christiansen S; Jahn UR; Meyer J; Scheld HH; Van Aken H; Kehrel BE; Hammel D
    Ann Thorac Surg; 2000 Mar; 69(3):774-7. PubMed ID: 10750760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. The TIFDED Study Group.
    Haemostasis; 1999; 29(6):310-7. PubMed ID: 10844404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
    Polkinghorne KR; McMahon LP; Becker GJ
    Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture.
    Gent M; Hirsh J; Ginsberg JS; Powers PJ; Levine MN; Geerts WH; Jay RM; Leclerc J; Neemeh JA; Turpie AG
    Circulation; 1996 Jan; 93(1):80-4. PubMed ID: 8616946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
    Aouifi A; Blanc P; Piriou V; Bastien OH; Ffrench P; Hanss M; Lehot JJ
    Ann Thorac Surg; 2001 Feb; 71(2):678-83. PubMed ID: 11235727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.